Shepherd Financial Partners LLC Has $657,000 Stake in Pfizer Inc. (NYSE:PFE)

Shepherd Financial Partners LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,718 shares of the biopharmaceutical company’s stock after selling 3,284 shares during the quarter. Shepherd Financial Partners LLC’s holdings in Pfizer were worth $657,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Trust Direct Indexing L.P. raised its position in Pfizer by 45.0% in the 1st quarter. First Trust Direct Indexing L.P. now owns 51,735 shares of the biopharmaceutical company’s stock valued at $1,436,000 after purchasing an additional 16,060 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Pfizer during the 1st quarter worth about $315,000. Norden Group LLC increased its position in Pfizer by 26.8% in the 1st quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock valued at $842,000 after acquiring an additional 6,404 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of Pfizer by 12.8% in the first quarter. Private Advisor Group LLC now owns 652,208 shares of the biopharmaceutical company’s stock worth $18,099,000 after acquiring an additional 74,168 shares during the last quarter. Finally, Mission Wealth Management LP lifted its position in shares of Pfizer by 2.8% during the first quarter. Mission Wealth Management LP now owns 73,894 shares of the biopharmaceutical company’s stock worth $2,051,000 after purchasing an additional 2,004 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Trading Up 0.2 %

NYSE PFE traded up $0.06 during trading on Friday, reaching $28.36. 12,827,420 shares of the stock traded hands, compared to its average volume of 37,103,188. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market cap of $160.71 billion, a price-to-earnings ratio of 38.38, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67. The stock’s 50-day moving average price is $29.05 and its 200 day moving average price is $28.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.92%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday. Finally, Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.